Charles River Laboratories International, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NYSE
Charles River Laboratories International, Inc. reported a net loss for the second quarter and first half of 2026, impacted by divestitures and increased tax expenses, though operating income saw an increase.
NYSE
Charles River Laboratories International, Inc. reported a slight revenue decrease for Q3 2025 and the nine months ended September 27, 2025, alongside a significant drop in net income for the nine-month period, as it navigates a cautious client spending environment and implements a comprehensive strategic review.
NYSE
Charles River Laboratories International, Inc. reported a significant decline in Q2 2025 net income and operating profit, primarily due to accelerated amortization and substantial restructuring costs, despite a slight revenue increase.
NYSE
10-Q: Charles River Labs Reports Lower Q1 Revenue and Operating Income Amidst Cautious Client Spending
Charles River Laboratories' Q1 2025 results reveal a decrease in revenue and operating income, primarily due to cautious client spending and restructuring activities.
NYSE
Charles River Laboratories experienced a slight revenue decrease in Q3 2024, alongside restructuring efforts impacting profitability.
NYSE
Charles River Laboratories' second-quarter results show a revenue decrease and a drop in operating income, influenced by a cautious spending environment and restructuring activities.
NYSE
Charles River Laboratories' first quarter results show a slight revenue decrease and a significant drop in operating income, influenced by restructuring costs and ongoing legal issues.